Document is current
Any future updates will be listed below
-
Authors
Yilmaz, Musa https://orcid.org/0000-0002-4498-4895
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Reville, Patrick https://orcid.org/0000-0001-8433-3360
Konopleva, Marina https://orcid.org/0000-0002-9347-2212
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
DiNardo, Courtney https://orcid.org/0000-0001-9003-0390
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Pemmaraju, Naveen https://orcid.org/0000-0002-1670-6513
Maiti, Abhishek
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Jain, Nitin
Issa, Ghayas https://orcid.org/0000-0002-4339-8683
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Ohanian, Maro
Pierce, Sherry
Tang, Guillin https://orcid.org/0000-0002-9482-4806
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Patel, Keyur https://orcid.org/0000-0001-5081-2427
Wang, Sa A.
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Andreeff, Michael https://orcid.org/0000-0002-1144-1958
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Daver, Naval https://orcid.org/0000-0001-7103-373X
- License Information
-
More Information
Article History
Received: 22 February 2022
Revised: 30 March 2022
Accepted: 7 April 2022
First Online: 2 May 2022
Competing interests
: ND has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, Astellas, Sobi, Hanmi, Fate, Gilead, Forty-Seven, Trillium, KAHR, KITE, and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Syndax, Astellas, Immunogen, Glycostem, Novartis, Celgene, AbbVie, Arch oncology, KITE, Gilead, Servier, Trillium, Shattuck labs, and Agios. MY received research funding from Pfizer and Daiichi Sankyo. The authors declare no competing interests.
